Imcyse S.A.
Records under this name other than the patents Imcyse S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.
Showing 1 to 9 of 9 · Back to Imcyse S.A.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,808,016 | Peptides and Methods for the Treatment of Diabetes Formerly held In force · High confidence | In force | High confidence | |
| US 11,407,795 | Peptides and Methods for the Treatment of Diabetes Formerly held In force · High confidence | In force | High confidence | |
| US 11,760,782 | Peptides and Methods for the Treatment of Diabetes Formerly held In force · High confidence | In force | High confidence | |
| US 10,023,847 | Immunogenic Peptides for Use in the Prevention And/Or Treatment of Infectious Diseases, Autoimmune Diseases, Immune Responses to Allofactors, Allergic Diseases, Tumors, Graft Rejection and Immune Responses Against Viral Vectors Used for Gene Therapy or Gene Vaccination Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 11,226,332 | Method for the detection, preparation and depletion of CD4+ t lymphocytes Lapsed on the fee record Ended Jan 18, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 18, 2026 | From the USPTO record |
| US 9,861,661 | Elimination of immune responses to viral vectors Lapsed on the fee record Ended Jan 9, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 9, 2026 | From the USPTO record |
| US 11,193,114 | Immunogenic Peptides for Use in the Prevention And/Or Treatment of Infectious Diseases, Autoimmune Diseases, Immune Responses to Allofactors, Allergic Diseases, Tumors, Graft Rejection and Immune Responses Against Viral Vectors Used for Gene Therapy or Gene Vaccination Lapsed on the fee record Ended Dec 7, 2025 · High confidence | Lapsed on the fee record | Ended Dec 7, 2025 | High confidence |
| US 10,982,196 | Immunotherapy targeting intracellular pathogens Lapsed on the fee record Ended Apr 20, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 20, 2025 | From the USPTO record |
| US 10,899,795 | Modified epitopes for boosting CD4+ T-cell responses Lapsed on the fee record Ended Jan 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 26, 2025 | From the USPTO record |